Aktis Oncology prices upsized US IPO at $18 per share
Aktis Oncology raised $318 million through its IPO priced at $18 per share.
View signal analysisAkoustis Technologies, Inc. · NASDAQ · Technology
Browse public AKTS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Aktis Oncology raised $318 million through its IPO priced at $18 per share.
View signal analysis →- Akoustis reported a quarterly loss of $0.14 per share, missing estimates by 16.67%. - Revenues for the quarter ended March 2024 were $7.51 million, lower than expected. - Despite underperformance, estimate revisions for Akoustis are favorable with a Zacks Rank #2. - Industry outlook for Semiconductors - Radio Frequency is in the bottom 7%. - Another stock, SentinelOne, is expected to post a quarterly loss of $0.05 per share. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis →- Wall Street expects AKTS to report increased earnings and revenues in March 2024. - Forecasted quarterly loss of $0.12 per share, revenue increase to $8.56 million. - Earnings ESP is -33.33%, potential negative deviation from consensus estimate. - Negative surprise history, difficult to predict if AKTS will beat consensus EPS. - Other factors besides earnings may influence AKTS stock movement post-earnings. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis →